,	Application No.	Applicant(s)
Notice of Allowability	09/127,364	YEDNOCK ET AL.
	Examiner	Art Unit
	David Lukton	1653
The MAILING DATE of this communication appearable All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communical IGHTS. This application is subjection.	application. If not included ation will be mailed in due course. THIS
1. This communication is responsive to <u>12/6/04</u> .		
2. The allowed claim(s) is/are 48-53,55 and 57.		
3. The drawings filed on 7/31/98 are accepted by the Examine	er.	
 4. Acknowledgment is made of a claim for foreign priority una) a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application No	D
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a re ENT of this application.	ply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINes reason(s) why the oath or dec	IER'S AMENDMENT or NOTICE OF laration is deficient.
 CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the 	on's Patent Drawing Review (P s Amendment / Comment or in the 84(c)) should be written on the dr	e Office action of
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT F 	SIT OF BIOLOGICAL MATERIA FOR THE DEPOSIT OF BIOLOG	AL must be submitted. Note the GICAL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summ Paper No./Mail 8), 7. ⊠ Examiner's Ame	Date <u>20050201</u> .
	•	

Pursuant to the directives of the amendment filed 12/6/04, claims 56, 58, 59 have been cancelled, and claims 48, 51, 55 amended. Claims 48-55 and 57 are now pending. Pursuant also to the following Examiner's Amendment, claims 48-53, 55 and 57 are now allowable.

 \diamondsuit

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. §1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.

- Cancel claim 54.
- In claim 48, line 1, delete "inflammatory disorders",
 and substitute therefor - an inflammatory disorder - .
- In claim 48, line 3, after "patient,", insert the following:

 and which disorder is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, viral meningitis, encephalitis, and ulcerative colitis
 and
- In claim 48, line 3, delete "which method comprises",
 and substitute therefor -- said method comprising -- .
- In claim 49, line 2, delete "condition",

and substitute therefor -- disorder --.

- In claim 51, line 1, delete "inflammatory disorders",
 and substitute therefor - an inflammatory disorder - .
- In claim 51, line 2, delete "disorders are", and substitute therefor: - disorder is -
- In claim 51, line 2, delete "involve", and substitute therefor: -- involves --.
- In claim 51 line 3, after "integrin ligand,", insert the following:
 - - and which disorder is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, viral meningitis, encephalitis, and ulcerative colitis -- .

Authorization for this Examiner's Amendment was given in a telephone conversation with Stephen Todd on 2/4/05.

 \diamond

Del Lylan 2/7/05

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber, can be reached at 571-272-0925. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

JONWEBER

SUPERVISORY PATENT EXAMINER